Processing

Please wait...

Settings

Settings

Goto Application

1. WO2011161699 - IMMUNOSUPPRESSION MODULATING COMPOUNDS

Publication Number WO/2011/161699
Publication Date 29.12.2011
International Application No. PCT/IN2011/000426
International Filing Date 27.06.2011
IPC
A61K 38/17 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
C07K 14/705 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
A61P 1/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
04for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 1/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
18for pancreatic disorders, e.g. pancreatic enzymes
A61P 11/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
A61P 13/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
Applicants
  • AURIGENE DISCOVERY TECHNOLOGIES LIMITED [IN]/[IN] (AllExceptUS)
  • SASIKUMAR, Pottayil, Govindan, Nair [IN]/[IN] (UsOnly)
  • RAMACHANDRA, Muralidhara [US]/[IN] (UsOnly)
  • VADLAMANI, Suresh, Kumar [IN]/[IN] (UsOnly)
  • VEMULA, Koteswara, Rao [IN]/[IN] (UsOnly)
  • SATYAM, Leena, Khare [GB]/[IN] (UsOnly)
  • SUBBARAO, Krishnaprasad [IN]/[IN] (UsOnly)
  • SHRIMALI, Rajeev, K. [IN]/[IN] (UsOnly)
  • KANDEPU, Sreenivas [IN]/[IN] (UsOnly)
Inventors
  • SASIKUMAR, Pottayil, Govindan, Nair
  • RAMACHANDRA, Muralidhara
  • VADLAMANI, Suresh, Kumar
  • VEMULA, Koteswara, Rao
  • SATYAM, Leena, Khare
  • SUBBARAO, Krishnaprasad
  • SHRIMALI, Rajeev, K.
  • KANDEPU, Sreenivas
Agents
  • MAJUMDAR, Subhatosh
Priority Data
1805/CHE/201025.06.2010IN
61/381,59310.09.2010US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) IMMUNOSUPPRESSION MODULATING COMPOUNDS
(FR) COMPOSÉS MODULATEURS DE L'IMMUNOSUPPRESSION
Abstract
(EN) The present invention provides immunosuppression compounds capable of inhibiting the programmed cell death 1 (PDl) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signaling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides an application of the compositions containing the peptide moieties for preventive and/or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of peptide moieties as a testing or diagnostic agent or a research agent for such a disease.
(FR) Cette invention concerne des composés d'immunosuppression capables d'inhiber la voie de signalisation de l'apoptose PD‑1. L'invention concerne par ailleurs des compositions peptidiques utilisées pour traiter le cancer ou d'infections via l'immunopotentialisation causée par l'inhibition du signalement immunosuppresseur induit par l'apoptose PD-1, PD-L1 ou PD-L2, et des traitements utilisant ces compositions, des substrats immunopotentiateurs inclus comme principe actif. Par ailleurs, l'invention concerne une application des compositions contenant les fractions peptidiques utilisées comme agents prophylactiques et/ou thérapeutiques pour traiter le cancer, les métastases, l'immunodéficience, une maladie infectieuse ou similaire, et une application des fractions peptidiques utilisées comme agent d'analyse, de diagnostic ou d'étude pour ce type de maladie.
Related patent documents
BR112012032850This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
THTH1201006745This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
Latest bibliographic data on file with the International Bureau